Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VIP152 |
Synonyms | |
Therapy Description |
BAY 1251152 is a selective inhibitor of P-TEFb/CDK9, which may lead to blockade of MCL1 and MYC transcription, resulting in antitumor activity (J Clin Oncol 36, 2018 (suppl; abstr 2507). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VIP152 | BAY 1251152|BAY1251152|BAY-1251152|VIP-152 | CDK9 Inhibitor 19 | VIP152 (BAY 1251152) selectively inhibits CDK9, potentially resulting in antitumor activity (PMID: 35046056, PMID: 32488087). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02635672 | Phase I | VIP152 | Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer | Recruiting | USA | 1 |
NCT04978779 | Phase I | VIP152 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | Recruiting | USA | 1 |